SR 48968: Clinical Trials

13 completed. 13 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	13	Completed 13

Follow SR 48968: new trials by email Literature Review of SR 48968 trials Research Report on SR 48968

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder saredutant (SR48968), paroxetine, placebo - Depressive Disorder, Major	Phase 3	Completed	Sanofi	825	2008-02-01	2016-05-26
An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder saredutant (SR48968), escitalopram, placebo - Major Depressive Disorder	Phase 3	Completed	Sanofi	643	2007-09-01	2016-05-24
A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression Saredutant - Depressive Disorder	Phase 3	Completed	Sanofi	125	2007-01-01	2012-02-17
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder Saredutant, Escitalopram, Placebo - Generalized Anxiety	Phase 3	Completed	Sanofi	365	2006-12-01	2016-05-24
An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder saredutant (SR48968), placebo, escitalopram - Depressive Disorder	Phase 3	Completed	Sanofi	393	2006-12-01	2016-05-24
A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder Saredutant - Anxiety	Phase 3	Completed	Sanofi	366	2006-10-01	2011-04-06
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder Saredutant, Placebo - Generalized Anxiety	Phase 3	Completed	Sanofi	428	2006-09-01	2016-05-24
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA) Saredutant (SR48968C), Placebo - Depressive Disorder	Phase 3	Completed	Sanofi	430	2006-05-01	2016-05-13
A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression Saredutant succinate (SR48968C) - Depressive Disorder	Phase 3	Completed	Sanofi	365	2005-05-01	2012-02-17
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression Saredutant succinate (SR48968C) - Depressive Disorder	Phase 3	Completed	Sanofi	460	2005-04-01	2012-02-17
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression Saredutant succinate (SR48968C) - Depressive Disorder	Phase 3	Completed	Sanofi	452	2005-04-01	2010-06-09
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression Saredutant succinate (SR48968C) - Depressive Disorder	Phase 3	Completed	Sanofi	467	2004-12-01	2018-04-20
An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression Saredutant succinate (SR48968C) - Depressive Disorder	Phase 3	Completed	Sanofi	465	2004-12-01	2008-12-23

Conditions studied

Depression (10)  ·  Depressive Disorder (8)  ·  Anxiety Disorders (3)  ·  Depressive Disorder, Major (3)  ·  Generalized Anxiety Disorder (2)

Sponsors

Sanofi (13)

Countries

United States (10)  ·  Mexico (5)  ·  Canada (4)  ·  France (4)  ·  Chile (3)  ·  Croatia (3)  ·  Czechia (3)  ·  Germany (3)  ·  Sweden (3)  ·  Estonia (2)  ·  Finland (2)  ·  Portugal (2)  ·  Russia (2)  ·  Turkey (Türkiye) (2)  ·  Argentina (1)